多汗症治疗市场规模、份额、成长分析、按类型、按治疗方法、按年龄、按最终用户、按地区 - 行业预测，2025-2032

2023年，全球多汗症治疗市场规模为6.712亿美元，在预测期内（2025-2032年）复合年增长率为5.4%，从2024年的7.0744亿美元增长到2032年，预计将增长至10.775亿美元。

由于研发投资的活性化和次发性多汗症盛行率的上升，多汗症治疗市场正在显着成长。由于没有永久治疗方法，止汗剂和外用溶液仍然是主要治疗方法。患者对创新治疗方案的偏好不断增加，促使公司增强其产品。根据 Jared Brackenrich 于 2021 年 10 月发表的一项研究，多汗症目前影响着约 3% 的美国人口，而这种状况影响社会、心理和职业功能。此外，有希望的治疗方法开发、有利的报销政策和公众意识的提高可能会推动需求。特别是，Brickell Biotech 的索吡溴铵凝胶的 3 期临床试验显示了先进多汗症治疗的强大未来性。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究

多汗症治疗市场规模：按类型和复合年增长率（2025-2032）

• 市场概况
• 腋窝多汗症
• 手掌多汗症
• 足底多汗症
• 其他类型

多汗症治疗市场规模：依治疗方法及复合年增长率（2025-2032）

• 市场概况
• 局部治疗
• 口腔医学
  • 抗胆碱能药物
  • 其他口服药物
• 肉毒毒素注射
• 离子电渗透疗法
• 手术治疗

多汗症治疗市场规模：依年龄及复合年增长率（2025-2032）

• 市场概况
• 直到 50 岁
• 50岁以上

多汗症治疗市场规模：按最终用户和复合年增长率（2025-2032）

• 市场概况
• 医院
• 门诊手术中心
• 皮肤科诊所
• 其他最终用户

多汗症治疗市场规模：按地区和复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• AbbVie Inc.（US）
• Avanor Healthcare Ltd.（UK）
• Brickell Biotech Inc.（US）
• Dermadry Laboratories Inc.（Canada）
• Dermavant Sciences Inc.（US）
• Hugel, Inc.（South Korea）
• Eirion Therapeutics, Inc.（US）
• Eli Lilly and Company（US）
• Intas Pharmaceuticals Ltd.（India）
• Kaken Pharmaceutical Co., Ltd.（Japan）
• Maruho Co., Ltd.（Japan）
• miraDry, Inc.（US）
• SweatBlock（US）
• Roivant Sciences Ltd.（Switzerland）
• Theravida, Inc.（US）
• Dr. August Wolff GmbH（Germany）
• Dr. Reddy's Laboratories Ltd.（India）
• GSK Plc（UK）
• Revance（US）
• NovaMedica（Russia）

结论和建议

Global Hyperhidrosis Treatment Market size was valued at USD 671.2 million in 2023 and is poised to grow from USD 707.44 million in 2024 to USD 1077.5 million by 2032, growing at a CAGR of 5.4% during the forecast period (2025-2032).

The hyperhidrosis treatment market is witnessing significant growth driven by heightened R&D investment and a rising prevalence of secondary hyperhidrosis disorders. Antiperspirants and topical solutions remain the frontline therapies as no permanent cure exists. The growing patient preference for innovative treatment options has spurred companies to enhance their offerings. Currently, hyperhidrosis affects about 3% of the U.S. population, according to a study published by Jared Brackenrich in October 2021, underscoring the condition's impact on social, psychological, and vocational functioning. Additionally, promising therapies in the pipeline, favorable reimbursement policies, and increasing public awareness are likely to fuel demand. Notably, Brickell Biotech's Phase 3 trials of sofpironium bromide gel indicate a strong future potential for advanced hyperhidrosis treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hyperhidrosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hyperhidrosis Treatment Market Segmental Analysis

Global Hyperhidrosis Treatment Market is segmented by Type, Treatment, Age, End-user and region. Based on Type, the market is segmented into Axillary hyperhidrosis, Palmar hyperhidrosis, Plantar hyperhidrosis and Other types. Based on Treatment, the market is segmented into Topical treatment, Oral medication, Botulinum toxin injections, Iontophoresis and Surgical treatment. Based on Age, the market is segmented into Up to 50 years and Above 50 years. Based on End-user, the market is segmented into Hospitals, Ambulatory surgical centers, Dermatology clinics and Other end-users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hyperhidrosis Treatment Market

The Global Hyperhidrosis Treatment market is driven by a growing interest among healthcare providers in exploring advanced therapies such as radiofrequency microneedling for hyperhidrosis patients. Researchers are particularly focused on assessing the long-term effectiveness of fractional microneedle radiofrequency treatments for individuals with primary axillary hyperhidrosis, utilizing the hyperhidrosis disease severity scale (HDSS) to measure significant improvements post-treatment. Additionally, tap water iontophoresis is gaining traction, demonstrating notable results in clinical trials for patients suffering from plantar and palmar hyperhidrosis. Innovations in treatment options are being propelled by recent successful studies, including the positive Phase 3 results from Brickell Biotech Inc. regarding sofpironium bromide gel, highlighting the market's potential for growth and enhanced patient quality of life.

Restraints in the Global Hyperhidrosis Treatment Market

The Global Hyperhidrosis Treatment market faces notable challenges, one of which is the limited duration of effectiveness associated with Botulinum toxin injections; patients often develop a reduced response to these treatments over time. Additionally, the financial implications and emotional strain on patients pose significant obstacles, as many insurance providers do not reimburse expenses related to hyperhidrosis treatments. This lack of coverage not only adds to the economic burden for individuals seeking relief but also contributes to their psychological distress, potentially leading to decreased treatment adherence and limiting market growth opportunities in this sector.

Market Trends of the Global Hyperhidrosis Treatment Market

The Global Hyperhidrosis Treatment market is witnessing significant growth, driven by an increasing awareness of excessive sweating conditions and the effectiveness of advanced treatment options like onabotulinumtoxinA (Botox). With its clinically proven ability to reduce sweating by 82-87% and long-lasting effects that can endure up to 14 months, Botox has become a preferred treatment choice among patients. The market is further propelled by innovations in minimally invasive procedures, a growing prevalence of hyperhidrosis, and a rise in disposable income allowing for aesthetic treatments. As demand expands, the market is poised for continued advancement through research and new therapeutic options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Hyperhidrosis Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Axillary hyperhidrosis
• Palmar hyperhidrosis
• Plantar hyperhidrosis
• Other types

Global Hyperhidrosis Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Topical treatment
• Oral medication
  • Anticholinergics
  • Other oral medications
• Botulinum toxin injections
• Iontophoresis
• Surgical treatment

Global Hyperhidrosis Treatment Market Size by Age & CAGR (2025-2032)

• Market Overview
• Up to 50 years
• Above 50 years

Global Hyperhidrosis Treatment Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Dermatology clinics
• Other end-users

Global Hyperhidrosis Treatment Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Age, End-user)
  • US
  • Canada
• Europe (Type, Treatment, Age, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Age, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Age, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Age, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avanor Healthcare Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Brickell Biotech Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermadry Laboratories Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermavant Sciences Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hugel, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eirion Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaken Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Maruho Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• miraDry, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SweatBlock (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roivant Sciences Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravida, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. August Wolff GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revance (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NovaMedica (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations